SecBot SecBot
8-K ·Filed Aug 6, 2026

NVAX

NOVAVAX INC
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago SEC0001000694-26-000019
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The raised revenue guidance and improved expense outlook are credit-positive signals, but the sharp YoY revenue decline and continued net loss keep the stock range-bound near-term. Monitor for Sanofi's CIC trial initiation (a $125M catalyst) and the mid-2027 tech transfer milestone ($75M) as the next major value-inflection events.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.74
T+0 close · Aug 6, 2026 · via day close
Latest settled
+30.23%
T+60 · $10.08
Vs SPY
+31.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $7.74entry
  2. T+1 · 3mo ago +2.71%α +2.10% · $7.95
  3. T+5 · 3mo ago +5.17%α +3.96% · $8.14
  4. T+20 · 3mo ago +33.59%α +32.99% · $10.34
  5. T+60 · 18d ago +30.23%α +31.90% · $10.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Novavax reported Q2 2026 total revenue of $57M, a 76% decline YoY from $239M, driven by the absence of a $175M BLA milestone and $27M Takeda amendment that benefited the prior year. The company posted a GAAP net loss of $53M ($-0.32 per share) versus net income of $107M in Q2 2025. However, Novavax raised its full-year 2026 Adjusted Total Revenue framework to $235M-$275M (from $230M-$270M) and improved GAAP combined R&D and SG&A expense guidance, signaling confidence in its partnership-driven strategy and cost discipline despite the quarterly revenue drop.

Key Financial Metrics

EPS
−$0.32
est −$0.38 · +15.8%
Revenue
$56.7M
est $53.3M · +6.4% · -76.3% YoY
Rating
in line
Guidance
$235M-$275M
raised

Key Facts

  • Q2 2026 total revenue was $57M, down 76% YoY from $239M.
  • GAAP net loss of $53M ($-0.32 per share) vs net income of $107M ($0.66) in Q2 2025.
  • EPS of $-0.32 beat consensus of $-0.38 by 16.6%.
  • Raised full-year 2026 Adjusted Total Revenue guidance to $235M-$275M from $230M-$270M.
  • Improved GAAP combined R&D and SG&A expense guidance to $370M-$410M from $380M-$420M.
  • Cash, equivalents, and marketable securities were $724M as of June 30, 2026.
  • Sanofi confirmed advanced discussions with regulators for Phase 3 COVID-19-Influenza Combination trial; initiation would trigger a $125M milestone.
  • Manufacturing tech transfer to Sanofi expected mid-2027, triggering a $75M milestone.

Financial Impact

Q2 2026 revenue of $57M (76% YoY decline); net loss of $53M vs net income of $107M in Q2 2025; raised FY2026 revenue guidance by $5M at midpoint to $235M-$275M.

revenuenet incomecash positionguidance

Risk Factors

  • Dependence on Sanofi partnership for future revenue and milestones; any delays in CIC trial or tech transfer would push catalysts out.
  • Continued net losses and negative stockholders' deficit of $190.7M raise long-term capital concerns despite current cash runway.
  • COVID-19 vaccine demand remains seasonal and unpredictable, limiting visibility on Nuvaxovid product sales.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001000694-26-000019
Document: prfinal.htm0001000694-26-000019
Document: 0001000694-26-000019-index-headers.html0001000694-26-000019
Document: 0001000694-26-000019-index.html0001000694-26-000019
Document: 0001000694-26-000019.txt0001000694-26-000019
8-K Data (Synthetic)0001000694-26-000019

Track record

9 reports on NVAX

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +25.51% at T+20 after the Oct 16, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $10.20 Now $8.06 −20.98% settles Nov 17
  2. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $9.78 to $8.76 Now $8.06 −17.59% ▼ −10.43% −13.72% vs SPY
  3. Oct 29, 202618d ago 8-K Bullish 5/10 Entry $10.08 to $10.78 Now $8.06 −20.04% ▲ +6.94% +9.65% vs SPY
  4. Oct 16, 20264w ago SC 13G Neutral 4/10 Entry $10.82 to $9.40 Now $8.06 −25.51% ▼ −13.12% −12.98% vs SPY
  5. Oct 16, 20264w ago SC 13D/A Bearish 6/10 Entry $10.82 to $9.40 Now $8.06 +25.51% ▲ +13.12% +12.98% vs SPY
  6. Aug 6, 202614w ago 8-K Neutral 5/10 Viewing Entry $7.74 to $8.14 Now $8.06 +4.13% ▲ +5.17% +3.96% vs SPY
  7. May 6, 202627w ago 8-K Neutral 4/10 Entry $9.36 to $9.62 Now $8.06 −13.89% ▲ +2.78% +1.65% vs SPY
  8. Apr 27, 202629w ago DEFA14A Neutral 2/10 Entry $8.07 to $8.03 Now $8.06 −0.12% ▼ −0.50% −0.90% vs SPY
  9. Feb 26, 202637w ago 8-K Bullish 8/10 Entry $11.19 to $9.99 Now $8.06 −27.97% ▼ −10.72% −9.60% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens Wed (10h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026